The oral antiamyloid drug tramiprosate benefits a subgroup of patients with ε4 alleles of the apolipoprotein E (APOE) gene. "Our plan is to study a well-defined population genetically — that's the homozygotes," said Dr Abushakra. "This is very much like a precision medicine approach that people have taken in oncology. It focuses on a certain genotype and should help improve the chances of success for this program." The paper was published online October 24 in the Journal of the Prevention of Alzheimer's Disease.